Prognosis
GSK, Sanofi Surge as US Judge Dismisses Zantac Cases
- Ruling slaps down ‘litigation-driven science,’ GSK says
- Judge rejects evidence of link between Zantac and cancer
Photographer: Gabby Jones/Bloomberg
This article is for subscribers only.
GSK Plc and Sanofi surged after a US judge rejected the scientific evidence behind claims heartburn drug Zantac can cause cancer, meaning the drugmakers don’t have to face more than 5,000 lawsuits.
GSK shares rose 16% in London trading and Sanofi gained 8.8% in Paris. The UK drugmaker welcomed the dismissal, saying the ruling slapped down “unreliable and litigation-driven science.”